{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:40:39Z","timestamp":1788273639443,"version":"build-2803163510"},"reference-count":146,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA57928"],"award-info":[{"award-number":["R01 DA57928"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01 AA28050"],"award-info":[{"award-number":["K01 AA28050"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AA27486"],"award-info":[{"award-number":["R01 AA27486"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R18 HS29774"],"award-info":[{"award-number":["R18 HS29774"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"the Brain & Behavior Research Foundation","doi-asserted-by":"crossref","award":["31329"],"award-info":[{"award-number":["31329"]}],"id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mayo Clinic Research Pipeline K2R Program"},{"name":"Terrance and Bette Noble Foundation"},{"DOI":"10.13039\/100014535","name":"Mayo Clinic Center for Individualized Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014535","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Opioid use disorder (OUD) affects over 40 million people worldwide, creating significant social and economic burdens. Medication for opioid use disorder (MOUD) is often considered the primary treatment approach for OUD. MOUD, including methadone, buprenorphine, and naltrexone, is effective for some, but its benefits may be limited by poor adherence to treatment recommendations. Immunopharmacotherapy offers an innovative approach by using vaccines to generate antibodies that neutralize opioids, blocking them from crossing the blood-brain barrier and reducing their psychoactive effects. To date, only 3 clinical trials for opioid vaccines have been published. While these studies demonstrated the potential of opioid vaccines for relapse prevention, there is currently no standardized protocol for evaluating their effectiveness. We have reviewed recent preclinical studies that demonstrated the efficacy of vaccines targeting opioids, including heroin, morphine, oxycodone, hydrocodone, and fentanyl. These studies showed that vaccines against opioids reduced drug reinforcement, decreased opioid-induced antinociception, and increased survival rates against lethal opioid doses. These studies also demonstrated the importance of vaccine formulation and the use of adjuvants in enhancing antibody production and specificity. Finally, we highlighted the strengths and concerns associated with the opioid vaccine treatment, including ethical considerations.<\/jats:p>","DOI":"10.1093\/ijnp\/pyaf005","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T12:43:27Z","timestamp":1737377007000},"source":"Crossref","is-referenced-by-count":7,"title":["The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3928-3194","authenticated-orcid":false,"given":"Mustafa","family":"Tuncturk","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic , Rochester, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Kushwaha","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic , Rochester, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"BS","given":"Robin M","family":"Heider","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic , Rochester, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Oesterle","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic , Rochester, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Weinshilboum","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic , Rochester, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3757-3924","authenticated-orcid":false,"given":"Ming-Fen","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic , Rochester, MN ,","place":["United States"]},{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic , Rochester, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"2025020413213347700_CIT0001","doi-asserted-by":"publisher","first-page":"108350","DOI":"10.1016\/j.drugalcdep.2020.108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume":"218","author":"Florence","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"2025020413213347700_CIT0002","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","article-title":"Global patterns of opioid use and dependence: harms to populations, interventions, and future action","volume":"394","author":"Degenhardt","year":"2019","journal-title":"Lancet."},{"key":"2025020413213347700_CIT0003","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.mayocp.2019.03.029","article-title":"Medication-assisted treatment for opioid-use disorder","volume":"94","author":"Oesterle","year":"2019","journal-title":"Mayo Clin Proc."},{"key":"2025020413213347700_CIT0004","doi-asserted-by":"publisher","first-page":"e223821","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Netw Open."},{"key":"2025020413213347700_CIT0005","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jsat.2018.03.001","article-title":"Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: a systematic review","volume":"89","author":"Maglione","year":"2018","journal-title":"J Subst Abuse Treat."},{"key":"2025020413213347700_CIT0006","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for management of opioid use disorder","volume":"76","author":"Koehl","year":"2019","journal-title":"Am J Health Syst Pharm."},{"key":"2025020413213347700_CIT0007","first-page":"416","article-title":"Opioid use disorder: medical treatment options","volume":"100","author":"Coffa","year":"2019","journal-title":"Am Fam Physician."},{"key":"2025020413213347700_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-019-1048-y","article-title":"Naloxone interventions in opioid overdoses: a systematic review protocol","volume":"8","author":"Shaw","year":"2019","journal-title":"Syst Rev."},{"key":"2025020413213347700_CIT0009","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cpdd.1312","article-title":"Pharmacokinetic properties of an FDA-approved intranasal nalmefene formulation for the treatment of opioid overdose","volume":"13","author":"Crystal","year":"2024","journal-title":"Clin Pharmacol Drug Dev."},{"key":"2025020413213347700_CIT0010","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Suboxone: rationale, science, misconceptions","volume":"18","author":"Velander","year":"2018","journal-title":"Ochsner J."},{"key":"2025020413213347700_CIT0011","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry."},{"key":"2025020413213347700_CIT0012","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jsat.2013.04.002","article-title":"Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification","volume":"45","author":"Bailey","year":"2013","journal-title":"J Subst Abuse Treat."},{"key":"2025020413213347700_CIT0013","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/itt.s370435","article-title":"A review of immunotherapeutic approaches for substance use disorders: current status and future prospects","volume":"11","author":"Celik","year":"2022","journal-title":"Immunotargets Ther"},{"key":"2025020413213347700_CIT0014","doi-asserted-by":"publisher","first-page":"107662","DOI":"10.1016\/j.neuropharm.2019.06.001","article-title":"Development of vaccines to treat opioid use disorders and reduce incidence of overdose","volume":"158","author":"Pravetoni","year":"2019","journal-title":"Neuropharmacology."},{"key":"2025020413213347700_CIT0015","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/252708a0","article-title":"Changes in heroin self-administration by a rhesus monkey after morphine immunisation","volume":"252","author":"Bonese","year":"1974","journal-title":"Nature."},{"key":"2025020413213347700_CIT0016","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/2051013614537818","article-title":"Vaccines against drugs of abuse: where are we now","volume":"2","author":"Kinsey","year":"2014","journal-title":"Ther Adv Vaccines."},{"key":"2025020413213347700_CIT0017","doi-asserted-by":"publisher","first-page":"5","DOI":"10.15252\/embr.201745322","article-title":"Vaccines to combat the opioid crisis: vaccines that prevent opioids and other substances of abuse from entering the brain could effectively treat addiction and abuse","volume":"19","author":"Olson","year":"2018","journal-title":"EMBO Rep."},{"key":"2025020413213347700_CIT0018","doi-asserted-by":"publisher","first-page":"2140552","DOI":"10.1080\/21645515.2022.2140552","article-title":"Vaccines as a preventive tool for substance use disorder: a systematic review including a meta-analysis on nicotine vaccines\u2019 immunogenicity","volume":"18","author":"Scendoni","year":"2022","journal-title":"Hum Vaccin Immunother."},{"key":"2025020413213347700_CIT0019","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/vaccines10111778","article-title":"Immunotherapies for the treatment of drug addiction","volume":"10","author":"Hossain","year":"2022","journal-title":"Vaccines."},{"key":"2025020413213347700_CIT0020","doi-asserted-by":"publisher","first-page":"860","DOI":"10.4049\/jimmunol.2100204","article-title":"Contribution of antibody-mediated effector functions to the mechanism of efficacy of vaccines for opioid use disorders","volume":"207","author":"Huseby Kelcher","year":"2021","journal-title":"J Immunol."},{"key":"2025020413213347700_CIT0021","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/13543784.2023.2173062","article-title":"Immunotherapeutic strategies for treating opioid use disorder and overdose","volume":"32","author":"Luba","year":"2023","journal-title":"Expert Opin Investig Drugs."},{"key":"2025020413213347700_CIT0022","doi-asserted-by":"publisher","first-page":"2122507","DOI":"10.1080\/21645515.2022.2122507","article-title":"Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development","volume":"18","author":"Hicks","year":"2022","journal-title":"Hum Vaccin Immunother."},{"key":"2025020413213347700_CIT0023","doi-asserted-by":"publisher","first-page":"10489","DOI":"10.1021\/jacs.9b04872","article-title":"Monoclonal antibodies for combating synthetic opioid intoxication","volume":"141","author":"Smith","year":"2019","journal-title":"J Am Chem Soc."},{"key":"2025020413213347700_CIT0024","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1124\/jpet.121.001048","article-title":"Pharmacological profiling of antifentanyl monoclonal antibodies in combination with naloxone in pre- and postexposure models of fentanyl toxicity","volume":"381","author":"Baehr","year":"2022","journal-title":"J Pharmacol Exp Ther."},{"key":"2025020413213347700_CIT0025","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.tips.2018.08.001","article-title":"Immunopharmacotherapies for treating opioid use disorder","volume":"39","author":"Banks","year":"2018","journal-title":"Trends Pharmacol Sci."},{"key":"2025020413213347700_CIT0026","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40263-020-00722-8","article-title":"Preclinical evaluation of vaccines to treat opioid use disorders: how close are we to a clinically viable therapeutic","volume":"34","author":"Townsend","year":"2020","journal-title":"CNS Drugs."},{"key":"2025020413213347700_CIT0027","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nyas.14329","article-title":"Current status of immunotherapies for addiction","volume":"1489","author":"Xu","year":"2021","journal-title":"Ann N Y Acad Sci."},{"key":"2025020413213347700_CIT0028","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1089\/hum.2012.163","article-title":"Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity","volume":"24","author":"De","year":"2013","journal-title":"Hum Gene Ther."},{"key":"2025020413213347700_CIT0029","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/pharmaceutics16010084","article-title":"Vaccines to treat substance use disorders: current status and future directions","volume":"16","author":"Lu","year":"2024","journal-title":"Pharmaceutics."},{"key":"2025020413213347700_CIT0030","doi-asserted-by":"publisher","first-page":"120098","DOI":"10.1016\/j.jns.2021.120098","article-title":"Current status of vaccines for substance use disorders: a brief review of human studies","volume":"434","author":"Truong","year":"2022","journal-title":"J Neurol Sci."},{"key":"2025020413213347700_CIT0031","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1124\/pr.117.013904","article-title":"Conjugate vaccine immunotherapy for substance use disorder","volume":"69","author":"Bremer","year":"2017","journal-title":"Pharmacol Rev."},{"key":"2025020413213347700_CIT0032","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry."},{"key":"2025020413213347700_CIT0033","author":"Substance Abuse and Mental Health Services Administration","year":"2023"},{"key":"2025020413213347700_CIT0034","author":"Substance Abuse and Mental Health Services Administration","year":"2024"},{"key":"2025020413213347700_CIT0035","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/00003088-200645040-00005","article-title":"Population pharmacokinetics of heroin and its major metabolites","volume":"45","author":"Rook","year":"2006","journal-title":"Clin Pharmacokinet."},{"key":"2025020413213347700_CIT0036","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2174\/187152711799219316","article-title":"Developing a vaccine against multiple psychoactive targets: a case study of heroin","volume":"10","author":"Neil Stowe","year":"2011","journal-title":"CNS Neurol Disord Drug Targets."},{"key":"2025020413213347700_CIT0037","doi-asserted-by":"publisher","first-page":"9036","DOI":"10.1073\/pnas.1219159110","article-title":"Dynamic vaccine blocks relapse to compulsive intake of heroin","volume":"110","author":"Schlosburg","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"2025020413213347700_CIT0038","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1126\/science.176.4039.1143","article-title":"Morphine-3-succinyl\u2014bovine serum albumin: an immunogenic hapten-protein conjugate","volume":"176","author":"Wainer","year":"1972","journal-title":"Science."},{"key":"2025020413213347700_CIT0039","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.4049\/jimmunol.114.4.1363","article-title":"Delayed clearance of morphine from the circulation of rabbits immunized with morphine-6-hemisuccinate bovine serum albumin","volume":"114","author":"Hill","year":"1975","journal-title":"J Immunol."},{"key":"2025020413213347700_CIT0040","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1126\/science.178.4067.1290","article-title":"Evidence for active immunity to morphine in mice","volume":"178","author":"Berkowitz","year":"1972","journal-title":"Science."},{"key":"2025020413213347700_CIT0041","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1470-8744.1999.tb00904.x","article-title":"Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development","volume":"30","author":"Akbarzadeh","year":"1999","journal-title":"Biotechnol Appl Biochem."},{"key":"2025020413213347700_CIT0042","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pnpbp.2013.05.012","article-title":"A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats","volume":"45","author":"Kosten","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"2025020413213347700_CIT0043","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3923\/pjbs.2010.1047.1051","article-title":"Safety of human therapeutic morphine vaccine employing Lohmann specific pathogen free eggs","volume":"13","author":"Farhangi","year":"2010","journal-title":"Pak J Biol Sci."},{"key":"2025020413213347700_CIT0044","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.112.201194","article-title":"Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats","volume":"344","author":"Raleigh","year":"2013","journal-title":"J Pharmacol Exp Ther."},{"key":"2025020413213347700_CIT0045","doi-asserted-by":"publisher","first-page":"e115696","DOI":"10.1371\/journal.pone.0115696","article-title":"Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats","volume":"9","author":"Raleigh","year":"2014","journal-title":"PLoS One."},{"key":"2025020413213347700_CIT0046","doi-asserted-by":"publisher","first-page":"127388","DOI":"10.1016\/j.bmcl.2020.127388","article-title":"Sulfonate-isosteric replacement examined within heroin-hapten vaccine design","volume":"30","author":"Belz","year":"2020","journal-title":"Bioorg Med Chem Lett."},{"key":"2025020413213347700_CIT0047","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1021\/jm200461m","article-title":"A vaccine strategy that induces protective immunity against heroin","volume":"54","author":"Stowe","year":"2011","journal-title":"J Med Chem."},{"key":"2025020413213347700_CIT0048","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1021\/mp400631w","article-title":"Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy","volume":"11","author":"Bremer","year":"2014","journal-title":"Mol Pharm."},{"key":"2025020413213347700_CIT0049","doi-asserted-by":"publisher","first-page":"13294","DOI":"10.1021\/jacs.0c05219","article-title":"Enhancement of a heroin vaccine through hapten deuteration","volume":"142","author":"Belz","year":"2020","journal-title":"J Am Chem Soc."},{"key":"2025020413213347700_CIT0050","doi-asserted-by":"publisher","first-page":"114345","DOI":"10.1016\/j.physbeh.2023.114345","article-title":"The effect of chronic stress on the immunogenicity and immunoprotection of the M6-TT vaccine in female mice","volume":"271","author":"M\u00e9ndez","year":"2023","journal-title":"Physiol Behav."},{"key":"2025020413213347700_CIT0051","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/acs.jmedchem.7b01427","article-title":"A stable heroin analogue that can serve as a vaccine hapten to induce antibodies that block the effects of heroin and its metabolites in rodents and that cross-react immunologically with related drugs of abuse","volume":"61","author":"Sulima","year":"2018","journal-title":"J Med Chem."},{"key":"2025020413213347700_CIT0052","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.vaccine.2014.01.028","article-title":"Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine","volume":"32","author":"Matyas","year":"2014","journal-title":"Vaccine."},{"key":"2025020413213347700_CIT0053","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1016\/j.vaccine.2013.04.027","article-title":"Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs","volume":"31","author":"Matyas","year":"2013","journal-title":"Vaccine."},{"key":"2025020413213347700_CIT0054","doi-asserted-by":"publisher","first-page":"7211","DOI":"10.1039\/c4ob01053a","article-title":"Synthesis and immunological effects of heroin vaccines","volume":"12","author":"Li","year":"2014","journal-title":"Org Biomol Chem."},{"key":"2025020413213347700_CIT0055","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1021\/acs.molpharmaceut.7b00933","article-title":"Enhancing efficacy and stability of an antiheroin vaccine: examination of antinociception, opioid binding profile, and lethality","volume":"15","author":"Hwang","year":"2018","journal-title":"Mol Pharm."},{"key":"2025020413213347700_CIT0056","doi-asserted-by":"publisher","first-page":"8601","DOI":"10.1021\/jacs.7b03334","article-title":"Development of a clinically viable heroin vaccine","volume":"139","author":"Bremer","year":"2017","journal-title":"J Am Chem Soc."},{"key":"2025020413213347700_CIT0057","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1039\/d1cb00029b","article-title":"Synthesis and immunological effects of C14-linked 4, 5-epoxymorphinan analogues as novel heroin vaccine haptens","volume":"2","author":"Gutman","year":"2021","journal-title":"RSC Chem Biol."},{"key":"2025020413213347700_CIT0058","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3390\/molecules27051553","article-title":"Design, synthesis, and in vivo evaluation of C1-linked 4, 5-epoxymorphinan haptens for heroin vaccines","volume":"27","author":"Sulima","year":"2022","journal-title":"Molecules."},{"key":"2025020413213347700_CIT0059","doi-asserted-by":"publisher","first-page":"173718","DOI":"10.1016\/j.ejphar.2020.173718","article-title":"Effect of the morphine\/heroin vaccine on opioid and non-opioid drug-induced antinociception in mice","volume":"891","author":"M\u00e9ndez","year":"2021","journal-title":"Eur J Pharmacol."},{"key":"2025020413213347700_CIT0060","doi-asserted-by":"publisher","first-page":"10776","DOI":"10.1021\/jm301262z","article-title":"Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance","volume":"55","author":"Bremer","year":"2012","journal-title":"J Med Chem."},{"key":"2025020413213347700_CIT0061","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41541-017-0013-9","article-title":"Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant","volume":"2","author":"Torres","year":"2017","journal-title":"NPJ Vaccines."},{"key":"2025020413213347700_CIT0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2157-7560.1000154","article-title":"Immunotherapy of 436 morphine addicts by therapeutic morphine vaccine in Kerman Province (I.R. Iran)","volume":"3","author":"Farhangi","year":"2012","journal-title":"J Vaccines Vaccin."},{"key":"2025020413213347700_CIT0063","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3923\/jpt.2009.30.35","article-title":"Immunotherapy of 347 volunteer outpatient morphine addicts by human therapeutic morphine vaccine in Kermanshah province of Iran","volume":"4","author":"Akbarzadeh","year":"2009","journal-title":"J Pharmacol Toxicol."},{"key":"2025020413213347700_CIT0064","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3923\/ajb.2007.58.65","article-title":"Study of human therapeutic morphine vaccine: safety and immunogenicity","volume":"2","author":"Akbarzadeh","year":"2007","journal-title":"Asian J Biochem."},{"key":"2025020413213347700_CIT0065","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/s0091-6749(96)80191-6","article-title":"Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines","volume":"98","author":"Sakaguchi","year":"1996","journal-title":"J Allergy Clin Immunol."},{"key":"2025020413213347700_CIT0066","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ab.2014.05.004","article-title":"Residual bovine serum albumin (BSA) quantitation in vaccines using automated Capillary Western technology","volume":"461","author":"Loughney","year":"2014","journal-title":"Anal Biochem."},{"key":"2025020413213347700_CIT0067","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.vaccine.2017.02.009","article-title":"Sensitization to bovine serum albumin as a possible cause of allergic reactions to vaccines","volume":"35","author":"de Silva","year":"2017","journal-title":"Vaccine."},{"key":"2025020413213347700_CIT0068","doi-asserted-by":"publisher","first-page":"1229439","DOI":"10.3389\/fpsyt.2023.1229439","article-title":"Oxycodone, an opioid like the others","volume":"14","author":"Marie","year":"2023","journal-title":"Front Psychiatry."},{"key":"2025020413213347700_CIT0069","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10571-020-01013-y","article-title":"Oxycodone in the opioid epidemic: high \u201cliking,\u201d\u2018wanting\u2019, and abuse liability","volume":"41","author":"Kibaly","year":"2021","journal-title":"Cell Mol Neurobiol."},{"key":"2025020413213347700_CIT0070","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41591-020-0875-7","article-title":"Generational trends in US opioid-overdose deaths","volume":"26","author":"Hall","year":"2020","journal-title":"Nat Med."},{"key":"2025020413213347700_CIT0071","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jamapsychiatry.2014.366","article-title":"The changing face of heroin use in the United States: a retrospective analysis of the past 50 years","volume":"71","author":"Cicero","year":"2014","journal-title":"JAMA Psychiatry."},{"key":"2025020413213347700_CIT0072","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40262-018-00731-3","article-title":"Updated clinical pharmacokinetics and pharmacodynamics of oxycodone","volume":"58","author":"Kinnunen","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"2025020413213347700_CIT0073","doi-asserted-by":"publisher","first-page":"e101807","DOI":"10.1371\/journal.pone.0101807","article-title":"Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PLoS One."},{"key":"2025020413213347700_CIT0074","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.neuropharm.2018.06.026","article-title":"Prophylactic vaccination protects against the development of oxycodone self-administration","volume":"138","author":"Nguyen","year":"2018","journal-title":"Neuropharmacology."},{"key":"2025020413213347700_CIT0075","doi-asserted-by":"publisher","first-page":"108653","DOI":"10.1016\/j.neuropharm.2021.108653","article-title":"Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder","volume":"195","author":"Raleigh","year":"2021","journal-title":"Neuropharmacology."},{"key":"2025020413213347700_CIT0076","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1124\/jpet.111.189506","article-title":"An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia","volume":"341","author":"Pravetoni","year":"2012","journal-title":"J Pharmacol Exp Ther."},{"key":"2025020413213347700_CIT0077","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1021\/jm3013745","article-title":"Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens","volume":"56","author":"Pravetoni","year":"2013","journal-title":"J Med Chem."},{"key":"2025020413213347700_CIT0078","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.1038\/s41598-018-23777-6","article-title":"Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose","volume":"8","author":"Laudenbach","year":"2018","journal-title":"Sci Rep."},{"key":"2025020413213347700_CIT0079","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jim.2014.01.010","article-title":"Hapten-specific naive B cells are biomarkers of vaccine efficacy against drugs of abuse","volume":"405","author":"Taylor","year":"2014","journal-title":"J Immunol Methods."},{"key":"2025020413213347700_CIT0080","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/21645515.2018.1558697","article-title":"Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders","volume":"15","author":"Robinson","year":"2019","journal-title":"Hum Vaccin Immunother."},{"key":"2025020413213347700_CIT0081","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1021\/acs.molpharmaceut.8b00592","article-title":"Preclinical efficacy and characterization of candidate vaccines for treatment of opioid use disorders using clinically viable carrier proteins","volume":"15","author":"Baruffaldi","year":"2018","journal-title":"Mol Pharm."},{"key":"2025020413213347700_CIT0082","doi-asserted-by":"crossref","first-page":"e0184876","DOI":"10.1371\/journal.pone.0184876","article-title":"Safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse","volume":"12","author":"Raleigh","year":"2017","journal-title":"PLoS One."},{"key":"2025020413213347700_CIT0083","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.4049\/jimmunol.2200605","article-title":"IL-4 predicts the efficacy of a candidate antioxycodone vaccine and alters vaccine-specific antibody-secreting cell proliferation in mice","volume":"210","author":"Crouse","year":"2023","journal-title":"J Immunol."},{"key":"2025020413213347700_CIT0084","doi-asserted-by":"publisher","first-page":"5926","DOI":"10.4049\/jimmunol.1500385","article-title":"The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse","volume":"194","author":"Laudenbach","year":"2015","journal-title":"J Immunol."},{"key":"2025020413213347700_CIT0085","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1016\/j.vaccine.2022.03.053","article-title":"Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder","volume":"40","author":"Hamid","year":"2022","journal-title":"Vaccine."},{"key":"2025020413213347700_CIT0086","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41541-020-00247-7","article-title":"Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders","volume":"5","author":"Crouse","year":"2020","journal-title":"NPJ Vaccines."},{"key":"2025020413213347700_CIT0087","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1080\/21645515.2021.1954442","article-title":"Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats","volume":"17","author":"Crouse","year":"2021","journal-title":"Hum Vaccin Immunother."},{"key":"2025020413213347700_CIT0088","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1016\/j.vaccine.2020.05.027","article-title":"Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity","volume":"38","author":"Gradinati","year":"2020","journal-title":"Vaccine."},{"key":"2025020413213347700_CIT0089","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.6b00977","article-title":"An advance in prescription opioid vaccines: overdose mortality reduction and extraordinary alteration of drug half-life","volume":"12","author":"Kimishima","year":"2017","journal-title":"ACS Chem Biol."},{"key":"2025020413213347700_CIT0090","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.117.247049","article-title":"Opioid dose-and route-dependent efficacy of oxycodone and heroin vaccines in rats","volume":"365","author":"Raleigh","year":"2018","journal-title":"J Pharmacol Exp Ther."},{"key":"2025020413213347700_CIT0091","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/add.15260","article-title":"Carfentanil and the rise and fall of overdose deaths in the United States","volume":"116","author":"Jalal","year":"2021","journal-title":"Addiction."},{"key":"2025020413213347700_CIT0092","doi-asserted-by":"crossref","first-page":"837","DOI":"10.15585\/mmwr.mm6533a2","article-title":"Fentanyl law enforcement submissions and increases in synthetic opioid\u2013involved overdose deaths\u201427 states, 2013\u20132014","volume":"65","author":"Gladden","year":"2016","journal-title":"Morb Mortal Wkly Rep."},{"key":"2025020413213347700_CIT0093","volume-title":"The Drug Overdose Toll in 2020 and Near-Term Actions for Addressing It","author":"Baumgartner","year":"2021"},{"key":"2025020413213347700_CIT0094","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuropharm.2017.10.016","article-title":"Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review","volume":"134","author":"Armenian","year":"2018","journal-title":"Neuropharmacology."},{"key":"2025020413213347700_CIT0095","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell."},{"key":"2025020413213347700_CIT0096","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41541-023-00694-y","article-title":"A lipidated TLR7\/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice","volume":"8","author":"Miller","year":"2023","journal-title":"NPJ Vaccines."},{"key":"2025020413213347700_CIT0097","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016","volume":"319","author":"Jones","year":"2018","journal-title":"JAMA."},{"key":"2025020413213347700_CIT0098","author":"CDC-NCHS. U.S"},{"key":"2025020413213347700_CIT0099","author":"Administration DE","year":"2024"},{"key":"2025020413213347700_CIT0100","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","article-title":"A review: fentanyl and non-pharmaceutical fentanyls","volume":"171","author":"Suzuki","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"2025020413213347700_CIT0101","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/wps.20846","article-title":"The epidemic of fentanyl misuse and overdoses: challenges and strategies","volume":"20","author":"Volkow","year":"2021","journal-title":"World Psychiatry."},{"key":"2025020413213347700_CIT0102","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/ADM.0000000000000324","article-title":"Misuse of novel synthetic opioids: a deadly new trend","volume":"11","author":"Prekupec","year":"2017","journal-title":"J Addict Med."},{"key":"2025020413213347700_CIT0103","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1038\/s41386-019-0418-4","article-title":"Utility of fentanyl vaccines: unique challenges posed by preventing opioid overdose and treating opioid use disorder","volume":"44","author":"Tunstall","year":"2019","journal-title":"Neuropsychopharmacology."},{"key":"2025020413213347700_CIT0104","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41398-019-0625-0","article-title":"The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies","volume":"9","author":"Han","year":"2019","journal-title":"Transl Psychiatry."},{"key":"2025020413213347700_CIT0105","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2017\u20132018","volume":"69","author":"Wilson","year":"2020","journal-title":"Morb Mortal Wkly Rep."},{"key":"2025020413213347700_CIT0106","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41386-019-0385-9","article-title":"Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats","volume":"44","author":"Townsend","year":"2019","journal-title":"Neuropsychopharmacology."},{"key":"2025020413213347700_CIT0107","doi-asserted-by":"publisher","first-page":"107730","DOI":"10.1016\/j.neuropharm.2019.107730","article-title":"Vaccine blunts fentanyl potency in male rhesus monkeys","volume":"158","author":"Tenney","year":"2019","journal-title":"Neuropharmacology."},{"key":"2025020413213347700_CIT0108","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.3390\/pharmaceutics14112290","article-title":"An immunconjugate vaccine alters distribution and reduces the antinociceptive, behavioral and physiological effects of fentanyl in male and female rats","volume":"14","author":"Haile","year":"2022","journal-title":"Pharmaceutics."},{"key":"2025020413213347700_CIT0109","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41541-021-00329-0","article-title":"Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge","volume":"6","author":"Stone","year":"2021","journal-title":"NPJ Vaccines."},{"key":"2025020413213347700_CIT0110","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1021\/acs.molpharmaceut.0c00497","article-title":"Novel vaccine that blunts fentanyl effects and sequesters ultrapotent fentanyl analogues","volume":"17","author":"Barrientos","year":"2020","journal-title":"Mol Pharm."},{"key":"2025020413213347700_CIT0111","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.1039\/d0cc02107e","article-title":"A fentanyl vaccine constructed upon opsonizing antibodies specific for the Gal\u03b11\u20133Gal epitope","volume":"56","author":"Wang","year":"2020","journal-title":"Chem Commun (Camb)."},{"key":"2025020413213347700_CIT0112","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1124\/jpet.118.253674","article-title":"A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats","volume":"368","author":"Raleigh","year":"2019","journal-title":"J Pharmacol Exp Ther."},{"key":"2025020413213347700_CIT0113","doi-asserted-by":"publisher","first-page":"14647","DOI":"10.1021\/acs.jmedchem.0c01042","article-title":"Therapeutic and prophylactic vaccines to counteract fentanyl use disorders and toxicity","volume":"63","author":"Robinson","year":"2020","journal-title":"J Med Chem."},{"key":"2025020413213347700_CIT0114","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1021\/acschembio.1c00026","article-title":"A highly efficacious carfentanil vaccine that blunts opioid-induced antinociception and respiratory depression","volume":"16","author":"Eubanks","year":"2021","journal-title":"ACS Chem Biol."},{"key":"2025020413213347700_CIT0115","doi-asserted-by":"publisher","first-page":"16584","DOI":"10.1021\/acsomega.2c00820","article-title":"Preclinical efficacy and selectivity of vaccines targeting fentanyl, alfentanil, sufentanil, and acetylfentanyl in rats","volume":"7","author":"Baehr","year":"2022","journal-title":"ACS Omega."},{"key":"2025020413213347700_CIT0116","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1002\/anie.201511654","article-title":"Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs","volume":"55","author":"Bremer","year":"2016","journal-title":"Angew Chem Int Ed Engl."},{"key":"2025020413213347700_CIT0117","doi-asserted-by":"publisher","first-page":"108348","DOI":"10.1016\/j.drugalcdep.2020.108348","article-title":"A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys","volume":"218","author":"Townsend","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"2025020413213347700_CIT0118","doi-asserted-by":"crossref","first-page":"1219985","DOI":"10.3389\/fphar.2023.1219985","article-title":"Development of a vaccine against the synthetic opioid U-47700","volume":"14","author":"Park","year":"2023","journal-title":"Front Pharmacol."},{"key":"2025020413213347700_CIT0119","doi-asserted-by":"publisher","first-page":"111775","DOI":"10.1016\/j.forsciint.2023.111775","article-title":"Non-fentanyl new synthetic opioids \u2013 an update","volume":"349","author":"Zawilska","year":"2023","journal-title":"Forensic Sci Int."},{"key":"2025020413213347700_CIT0120","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1021\/acs.jmedchem.1c01967","article-title":"A Vaccine against benzimidazole-derived new psychoactive substances that are more potent than fentanyl","volume":"65","author":"Lee","year":"2022","journal-title":"J Med Chem."},{"key":"2025020413213347700_CIT0121","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","article-title":"Fentanyl in the US heroin supply: a rapidly changing risk environment","volume":"46","author":"Ciccarone","year":"2017","journal-title":"Int J Drug Policy."},{"key":"2025020413213347700_CIT0122","doi-asserted-by":"publisher","first-page":"j4355","DOI":"10.1136\/bmj.j4355","article-title":"Epidemic of deaths from fentanyl overdose","volume":"358","author":"Soc\u00edas","year":"2017","journal-title":"BMJ."},{"key":"2025020413213347700_CIT0123","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1001\/jama.2017.13358","article-title":"Reframing the opioid epidemic as a national emergency","volume":"318","author":"Gostin","year":"2017","journal-title":"JAMA."},{"key":"2025020413213347700_CIT0124","doi-asserted-by":"publisher","first-page":"ENEURO.0323","DOI":"10.1523\/ENEURO.0323-17.2017","article-title":"Heroin contaminated with fentanyl dramatically enhances brain hypoxia and induces brain hypothermia","volume":"4","author":"Solis","year":"2017","journal-title":"eNeuro"},{"key":"2025020413213347700_CIT0125","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13543784.2023.2187286","article-title":"The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis","volume":"32","author":"Martinez","year":"2023","journal-title":"Expert Opin Investig Drugs."},{"key":"2025020413213347700_CIT0126","doi-asserted-by":"publisher","first-page":"11537","DOI":"10.1021\/acsomega.8b01478","article-title":"Improved admixture vaccine of fentanyl and heroin hapten immunoconjugates: antinociceptive evaluation of fentanyl-contaminated heroin","volume":"3","author":"Hwang","year":"2018","journal-title":"ACS Omega."},{"key":"2025020413213347700_CIT0127","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1021\/acschemneuro.8b00079","article-title":"Efficacious vaccine against heroin contaminated with fentanyl","volume":"9","author":"Hwang","year":"2018","journal-title":"ACS Chem Neurosci."},{"key":"2025020413213347700_CIT0128","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1021\/acs.bioconjchem.1c00179","article-title":"Bivalent conjugate vaccine induces dual immunogenic response that attenuates heroin and fentanyl effects in mice","volume":"32","author":"Barrientos","year":"2021","journal-title":"Bioconjug Chem."},{"key":"2025020413213347700_CIT0129","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1021\/acs.molpharmaceut.0c00837","article-title":"Developing translational vaccines against heroin and fentanyl through investigation of adjuvants and stability","volume":"18","author":"Blake","year":"2020","journal-title":"Mol Pharm."},{"key":"2025020413213347700_CIT0130","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1021\/acs.molpharmaceut.8b01296","article-title":"Formulation and characterization of conjugate vaccines to reduce opioid use disorders suitable for pharmaceutical manufacturing and clinical evaluation","volume":"16","author":"Baruffaldi","year":"2019","journal-title":"Mol Pharm."},{"key":"2025020413213347700_CIT0131","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1021\/acsptsci.1c00260","article-title":"Efficacy and selectivity of monovalent and bivalent vaccination strategies to protect against exposure to carfentanil, fentanyl, and their mixtures in rats","volume":"5","author":"Crouse","year":"2022","journal-title":"ACS Pharmacol Transl Sci."},{"key":"2025020413213347700_CIT0132","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1021\/acschemneuro.0c00064","article-title":"Evaluation of a dual fentanyl\/heroin vaccine on the antinociceptive and reinforcing effects of a fentanyl\/heroin mixture in male and female rats","volume":"11","author":"Townsend","year":"2020","journal-title":"ACS Chem Neurosci."},{"key":"2025020413213347700_CIT0133","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1016\/j.vaccine.2012.04.101","article-title":"Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats","volume":"30","author":"Pravetoni","year":"2012","journal-title":"Vaccine."},{"key":"2025020413213347700_CIT0134","doi-asserted-by":"publisher","first-page":"116225","DOI":"10.1016\/j.bmc.2021.116225","article-title":"Improvements on a chemically contiguous hapten for a vaccine to address fentanyl-contaminated heroin","volume":"41","author":"Park","year":"2021","journal-title":"Bioorg Med Chem."},{"key":"2025020413213347700_CIT0135","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1186\/s12889-022-14506-w","article-title":"Concurrent use of opioids and stimulants and risk of fatal overdose: a cohort study","volume":"22","author":"Palis","year":"2022","journal-title":"BMC Public Health."},{"key":"2025020413213347700_CIT0136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12910-021-00599-2","article-title":"Pharmacy stakeholder reports on ethical and logistical considerations in anti-opioid vaccine development","volume":"22","author":"Wartenweiler","year":"2021","journal-title":"BMC Med Ethics."},{"key":"2025020413213347700_CIT0137","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/ni.2321","article-title":"Immune to addiction: the ethical dimensions of vaccines against substance abuse","volume":"13","author":"Young","year":"2012","journal-title":"Nat Immunol."},{"key":"2025020413213347700_CIT0138","first-page":"95","volume-title":"Emerging Neurobiological Treatments of Addiction: Ethical and Public Policy Considerations.","author":"Carter","year":"2012"},{"key":"2025020413213347700_CIT0139","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/978-3-319-23150-1_21","article-title":"Ethical considerations of biologics to treat substance use disorders. In:","volume-title":"Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes","author":"Montoya","year":"2016"},{"key":"2025020413213347700_CIT0140","doi-asserted-by":"crossref","first-page":"126324","DOI":"10.1016\/j.vaccine.2024.126324","article-title":"Social complexity of a fentanyl vaccine to prevent opioid overdose conference proceedings: Radcliffe Institute for Advanced Study conference proceedings","volume":"44","author":"Weitzman","year":"2024","journal-title":"Vaccine."},{"key":"2025020413213347700_CIT0141","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2011.281","article-title":"Vaccines against drug abuse","volume":"91","author":"Shen","year":"2012","journal-title":"Clin Pharmacol Ther."},{"key":"2025020413213347700_CIT0142","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.bbi.2019.06.002","article-title":"Psychosis as an adverse effect of monoclonal antibody immunotherapy","volume":"81","author":"Essali","year":"2019","journal-title":"Brain Behav Immun."},{"key":"2025020413213347700_CIT0143","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/978-981-33-6044-0_25","article-title":"Vaccination and immunotherapy for major depression","volume":"1305","author":"Evrensel","year":"2021","journal-title":"Adv Exp Med Biol."},{"key":"2025020413213347700_CIT0144","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41398-023-02545-9","article-title":"Autoantibodies in patients with obsessive-compulsive disorder: a systematic review","volume":"13","author":"Denzel","year":"2023","journal-title":"Transl Psychiatry."},{"key":"2025020413213347700_CIT0145","doi-asserted-by":"crossref","first-page":"S582","DOI":"10.1192\/j.eurpsy.2023.1217","article-title":"Immunotherapy in autism spectrum disorder; a case series","volume":"66","author":"Agdere","year":"2023","journal-title":"Eur Psychiatry."},{"key":"2025020413213347700_CIT0146","first-page":"191","article-title":"Immunotherapy: an approach to treat Alzheimer\u2019s disease and autism spectrum disorder","volume-title":"Autism Spectrum Disorder and Alzheimer\u2019s Disease: Advances in Research","author":"Ma\u2019arfi","year":"2022"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf005\/61517897\/pyaf005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf005\/61517897\/pyaf005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf005\/61517897\/pyaf005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T13:21:58Z","timestamp":1738675318000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf005\/7964463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":146,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf005","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,1,20]]},"article-number":"pyaf005"}}